New nerve blocks to reduce pain after heart and lung surgery
New Truncal Nerve Blocks for Thoracoscopic Surgery and Open Heart Surgery.
This study is testing two new ways to block pain after heart and lung surgeries to see if they can help patients feel better and use less pain medication.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Sponsor | Tampere University Hospital Academic / other |
| Locations | 1 site (Tampere) |
| Trial ID | NCT03704753 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates two innovative nerve block techniques aimed at reducing postoperative pain in patients undergoing thoracoscopic lung surgery and open heart surgery. The first sub-study evaluates the effectiveness of the Serratus Anterior Plane block (SAPB) in minimizing opioid consumption, comparing different methods of administration. The second sub-study focuses on the Subpectoral Interfascial Plane block (SIP) to assess its impact on pain management after medial sternotomy. Patients will be randomly assigned to various treatment groups to determine the most effective approach.
Who should consider this trial
Good fit: Ideal candidates include individuals scheduled for elective thoracoscopic lung surgery or elective open heart valve surgery.
Not a fit: Patients with diabetes type 1 complications, chronic pain, or those currently using opioids or certain antidepressants may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could significantly reduce opioid use and improve pain management for patients undergoing thoracic and cardiac surgeries.
How similar studies have performed: Previous studies have shown promising results with similar nerve block techniques, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Elective thoracoscopic lung surgery or elective open heart valve surgery Exclusion Criteria: * DM1 with complications, lack of co-operation, refusal, chronic pain, chronic intake of opioids or use of SNRI or tricyclic antidepressants.
Where this trial is running
Tampere
- Tampere Heart Hospital — Tampere, Finland (Recruiting)
Study contacts
- Study coordinator: Antti J Kalli, MD
- Email: antti.kalli@sydansairaala.fi
- Phone: 0500723498
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.